April 9 (Reuters) - Morphotek:
* LICENSED ITS ERIBULIN-LINKER PAYLOAD TO BLISS BIOPHARMACEUTICAL CO OF CHINA
* LICENSING AGREEMENT WITH BLISSBIO INCLUDES UPFRONT PAYMENT, MILESTONES, SALES ROYALTY PAYMENTS, WHICH ARE UNDISCLOSED
* BLISSBIO HAS EXCLUSIVITY OPTION TO EXPAND TERRITORY BEYOND CHINA & TO DEVELOP THERAPEUTIC ADCS TO 2 ADDITIONAL ONCOLOGY TARGETS
* AGREEMENT GRANTS BLISSBIO EXCLUSIVE RIGHT TO USE ERIBULIN-LINKER PAYLOAD TO DEVELOP THERAPEUTIC ADC AGAINST ONCOLOGY TARGET FOR CHINA MARKET Source text for Eikon: Further company coverage:
